Cabot (NYSE:CBT – Get Free Report) issued its quarterly earnings results on Tuesday. The specialty chemicals company reported $1.61 earnings per share for the quarter, topping analysts’ consensus estimates of $1.47 by $0.14, Zacks reports. Cabot had a net margin of 8.62% and a return on equity of 22.82%. Cabot updated its FY 2026 guidance to 6.000-6.50 EPS.
Cabot Price Performance
CBT stock traded up $3.12 during midday trading on Tuesday, reaching $78.97. 500,438 shares of the stock were exchanged, compared to its average volume of 433,033. Cabot has a 52 week low of $58.33 and a 52 week high of $83.71. The company has a fifty day moving average price of $73.60 and a 200 day moving average price of $70.18. The company has a debt-to-equity ratio of 0.49, a current ratio of 1.67 and a quick ratio of 1.09. The stock has a market capitalization of $4.12 billion, a PE ratio of 13.83, a P/E/G ratio of 10.20 and a beta of 0.78.
Cabot Increases Dividend
The company also recently disclosed a quarterly dividend, which will be paid on Friday, June 12th. Investors of record on Friday, May 29th will be given a dividend of $0.4725 per share. The ex-dividend date is Friday, May 29th. This represents a $1.89 dividend on an annualized basis and a yield of 2.4%. This is an increase from Cabot’s previous quarterly dividend of $0.45. Cabot’s dividend payout ratio is presently 31.52%.
Analysts Set New Price Targets
Get Our Latest Analysis on CBT
Institutional Trading of Cabot
Several hedge funds and other institutional investors have recently made changes to their positions in CBT. NewEdge Advisors LLC raised its holdings in Cabot by 2,559.5% in the 1st quarter. NewEdge Advisors LLC now owns 984 shares of the specialty chemicals company’s stock valued at $82,000 after buying an additional 947 shares during the last quarter. Goldman Sachs Group Inc. grew its holdings in Cabot by 32.5% during the 1st quarter. Goldman Sachs Group Inc. now owns 442,646 shares of the specialty chemicals company’s stock worth $36,802,000 after acquiring an additional 108,645 shares during the last quarter. Empowered Funds LLC increased its position in Cabot by 102.6% in the 1st quarter. Empowered Funds LLC now owns 28,162 shares of the specialty chemicals company’s stock valued at $2,341,000 after acquiring an additional 14,260 shares during the period. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC raised its stake in shares of Cabot by 3.4% during the first quarter. UBS AM A Distinct Business Unit of UBS Asset Management Americas LLC now owns 122,022 shares of the specialty chemicals company’s stock valued at $10,145,000 after acquiring an additional 4,048 shares during the last quarter. Finally, Geneos Wealth Management Inc. lifted its holdings in shares of Cabot by 409.0% during the first quarter. Geneos Wealth Management Inc. now owns 453 shares of the specialty chemicals company’s stock worth $38,000 after purchasing an additional 364 shares during the period. 93.18% of the stock is currently owned by institutional investors.
Cabot Company Profile
Cabot Corporation is a global specialty chemicals and performance materials company headquartered in Boston, Massachusetts. Founded in 1882 by Godfrey Lowell Cabot, the company has grown into a diversified manufacturer with operations across North America, Europe, Asia and Latin America. Cabot serves a wide range of end markets, including automotive, industrial, energy, and consumer products, supplying essential ingredients that enhance performance, durability and functionality.
The company operates two primary segments: Reinforcement Materials and Performance Materials.
Further Reading
Receive News & Ratings for Cabot Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Cabot and related companies with MarketBeat.com's FREE daily email newsletter.
